Nevertheless, previous studies in animal models of ALD have shown that FXR activation by FXR agonists, including obeticholic acid and fexaramine, or an FGF15 orthologue, decreased ethanol-induced liver injury, steatosis, and inflammation by decreasing hepatic expression of Cyp7a1 and modulating lipid metabolism without any significant changes in the BA pool [12,33]. Here, NR1H4 is linked to steatosis.